Mishra L D, Sinha G K, Bhaskar Rao P, Sharma V, Satya K, Gairola R
Department of Anesthesiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221 005, India.
J Neurosurg Anesthesiol. 2005 Oct;17(4):193-8. doi: 10.1097/01.ana.0000181719.86978.05.
In a randomized, double blind, placebo controlled study; the acceptability, efficacy and safety of injectable midazolam as oral premedicant in children was evaluated. One hundred children (ASA 1,2) aged 6 months to 6 years, undergoing elective neurosurgical operations, like meningomyelocele, meningo-encephalocele, ventriculo peritoneal and other shunts and craniotomies for tumour decompression etc., were included in the study. The patients were randomly assigned to one of four groups (A, B, C, D) receiving respectively saline or 0.50, 0.75 and 1.0 mg/kg midazolam in honey, 45 min before separation from parents. All received identical general anesthesia (GA). Age, sex, weight, heart rate, blood pressure, respiratory rate, saturation (SaO2), reaction to parent's separation, sedation score and duration of anesthesia, recovery conditions and side effects were noted. We found no difference in age, sex, weight, patient acceptability vomiting after ingestion and duration of anesthesia between groups. Even though many children resisted the placement of premedicant in the mouth, only three children spat it out and none vomited after swallowing. The reaction to separation from parents was better after midazolam premedication. However, on reaching the operating room, 24% children (placebo-60%) were found anxious after 0.50 mg/kg, but 12% were deeply sedated after a dose of 1.0 mg/kg. Recovery was similar in groups A, B and C except that more (48%) patients were anxious in group A. Recovery, however was delayed in 16% patients of group D. Though, fewer complications were reported during recovery after midazolam than placebo premedication, they were minimal in the 0.75 mg/kg group. We concluded that giving injectable midazolam orally as premedication in pediatric age group scheduled for neurosurgical operations is acceptable, effective and safe in 0.75 mg/kg dose. While 0.50 mg/kg is less effective, 1.0 mg/kg does not offer any additional benefit over 0.75 mg/kg but does delay recovery and may compromise safety.
在一项随机、双盲、安慰剂对照研究中,评估了注射用咪达唑仑作为儿童口服术前用药的可接受性、疗效和安全性。本研究纳入了100名年龄在6个月至6岁之间、接受择期神经外科手术(如脊髓脊膜膨出、脑膜脑膨出、脑室腹腔分流术及其他分流术以及用于肿瘤减压等的开颅手术)的儿童(ASA 1、2级)。患者被随机分为四组(A、B、C、D),分别在与父母分离前45分钟接受生理盐水或0.50、0.75和1.0mg/kg咪达唑仑加蜂蜜。所有患者均接受相同的全身麻醉(GA)。记录年龄、性别、体重、心率、血压、呼吸频率、血氧饱和度(SaO2)、对与父母分离的反应、镇静评分、麻醉持续时间、恢复情况及副作用。我们发现各组之间在年龄、性别、体重、患者接受度、摄入后呕吐情况及麻醉持续时间方面无差异。尽管许多儿童抗拒将术前用药放入口中,但只有3名儿童吐出,吞咽后无一人呕吐。咪达唑仑术前用药后对与父母分离的反应更好。然而,到达手术室时,0.50mg/kg组有24%的儿童(安慰剂组为60%)表现焦虑,但1.0mg/kg剂量组有12%的儿童深度镇静。A、B和C组的恢复情况相似,只是A组中更多(48%)的患者表现焦虑。然而,D组有16%的患者恢复延迟。虽然与安慰剂术前用药相比,咪达唑仑术后恢复期间报告的并发症较少,但0.75mg/kg组的并发症最少。我们得出结论,对于计划进行神经外科手术的儿童年龄组,口服注射用咪达唑仑作为术前用药,0.75mg/kg剂量是可接受、有效且安全的。0.50mg/kg效果较差,1.0mg/kg相比0.75mg/kg没有额外益处,但会延迟恢复且可能影响安全性。